In-vitro sulfation of piceatannol by human liver cytosol and recombinant sulfotransferases

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 2, 2009, Pages 185-191

  Miksits, Michaela ^a   Sulyok, Michael ^b   Schuhmacher, Rainer ^b   Szekeres, Thomas ^c   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Liver; Piceatannol; Sulfation

Indexed keywords

ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; DRUG METABOLITE; ISOPROTEIN; PICEATANNOL; POLYPHENOL; RECOMBINANT ENZYME; SULFATE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; SULFOTRANSFERASE 1A2; SULFOTRANSFERASE 1A3; SULFOTRANSFERASE 1E1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIETARY INTAKE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SULFATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE COMPLEX; GRAPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; KINETICS; LIQUID CHROMATOGRAPHY; LIVER CYTOSOL; MALE; MASS SPECTROMETRY; WINE;

EID: 59049086506     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.02.0007     Document Type: Article

References (27)

1. Seow CJ et al. Piceatannol, a Syk-selective tyrosine kinase inhibitor, attenuated antigen challenge of guinea pig airways in vitro. Eur J Pharmacol 2002; 443: 189-196.
2. Murias M et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 2005; 69: 903-912.
3. Ovesná Z et al. Antioxidant activity of resveratrol, piceatannol and 3,3′,4,4′,5,5′-hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol Rep 2006; 16: 617-624.
4. Murias M et al. Resveratrol analogues as selective cyclo-oxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004; 12: 5571-5578.
5. Wieder T et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 2001; 15: 1735-1742.
6. Wolter F et al. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002; 132: 298-302.
7. Larrosa M et al. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr 2004; 43: 275-284.
8. Kuo PL, Hsu YL. The grape and wine constituent piceatannol inhibits proliferation of human bladder cancer cells via blocking cell cycle progression and inducing Fas/membrane bound Fas ligand-mediated apoptotic pathway. Mol Nutr Food Res 2008; 52: 408-418.
9. Fritzer-Szekeres M et al. Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells - synergism with Ara-C. Int J Oncol 2008; 33: 887-892.
10. Roupe K et al. Determination of piceatannol in rat serum and liver microsomes: pharmacokinetics and phase I and II biotransformation. Biomed Chromatogr 2004; 18: 486-491.
11. Yu C et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002; 19: 1907-1914.
12. Walle T et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382.
13. Murias M et al. Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. Cancer Lett 2008; 261: 172-182.
14. Lindsay J et al. Structure, function and polymorphism of human cytosolic sulfotransferases. Curr Drug Metab 2008; 9: 99-105.
15. Coughtrie MW. Sulfation through the looking glass - recent advances in sulfotransferase research for the curious. Pharmaco-genomics J 2002; 2: 297-308.
16. Miksits M et al. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT1 Al and SULT1E1. Xenobiotica 2005; 35: 1101-1119.
17. Hutzler JM, Tracy TS. Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 2002; 30: 355-362.
18. Anderson RJ et al. Sulfation of minoxidil by multiple human cytosolic sulfotransferases. Chem Biol Interact 1998; 109: 53-67.
19. Leilich G et al. Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application. Arzneimittelforschungen 1980; 30:949-953.
20. Garay RP et al. Evidence for (×)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. Eur J Pharmacol 1995; 274: 175-180.
21. Zuckerman A et al. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate. Brain Res 1999; 842: 1-5.
22. Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 2000; 129: 141-170.
23. Teubner W et al. Identification and localization of soluble sulfotransferases in the human gastrointestinal tract. Biochem J 2007; 404: 207-215.
24. Meinl W et al. Sulfotransferase forms expressed in human intestinal Caco-2 and TC7 cells at varying stages of differentiation and role in benzo[a]pyrene metabolism. Drug Metab Dispos 2008; 36: 276-283.
25. Wang J et al. Expression and characterization of a novel thyroid hormone-sulfating form of cytosolic sulfotransferase from human liver. Mol Pharmacol 1998; 53: 274-282.
26. Roupe K et al. Pharmacokinetics of selected stilbenes: rhapontigenin, piceatannol and pinosylvin in rats. J Pharm Pharmacol 2006; 58: 1443-1450.
27. Pasqualini JR, Chetrite GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005; 93: 221-236.